Aptamer Screening via HT-SELEX (High-Throughput Systematic Evolution of Ligands by Exponential Enrichment) is the modern, powerful method for discovering aptamers. Let’s break down what this service entails, its process, advantages, and key considerations.
First, a quick reminder: Aptamers are single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (proteins, small molecules, cells, viruses) with high affinity and specificity, analogous to antibodies. They are often called “chemical antibodies.”
Traditional SELEX is iterative and low-throughput. HT-SELEX supercharges this process by integrating:
Next-Generation Sequencing (NGS): To analyze the entire aptamer pool at each round.
Advanced Bioinformatics: To identify binding motifs and track enrichment.
Automation: Using robotics for partitioning (e.g., magnetic beads, microfluidics) to increase throughput and reproducibility.
This results in a faster, more efficient, and data-driven screening process.
A typical service provider will follow these steps:
1. Project Design & Library Synthesis
Target Preparation: You provide the target (recombinant protein, small molecule conjugate, whole cell, etc.). Its purity and stability are critical.
Library Design: A randomized oligonucleotide library is synthesized (typically 10^14 – 10^15 unique sequences). Libraries can be DNA, RNA, or modified nucleotides (e.g., SOMAmers) for enhanced stability and affinity.
2. The Selection Rounds (Cycles of Binding, Partitioning, and Amplification)
Incubation: The library is incubated with the target under defined conditions (buffer, temperature).
Partitioning: Bound sequences are separated from unbound ones. Common methods:
Magnetic Bead-Based: Target is immobilized on beads.
Membrane Filtration: For protein targets.
Capillary Electrophoresis (CE-SELEX): High-resolution separation.
Cell-SELEX: Using live cells as complex targets.
Elution & Amplification: Bound aptamers are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA).
Counter-Selection (Negative Selection): Often included to remove sequences that bind to the immobilization matrix or non-target components (e.g., non-target proteins).
3. High-Throughput Sequencing & Analysis (The “HT” Core)
After each key round (e.g., rounds 3, 5, 7, etc.), the enriched pool is sequenced using NGS.
Bioinformatics Analysis:
Reads Counting & Clustering: Identifies sequences that are enriched over successive rounds.
Motif Discovery: Finds conserved sequence or structural motifs responsible for binding.
Family Analysis: Groups similar sequences into families.
Tracking Enrichment: Shows which sequences/families are becoming more abundant.
4. Candidate Selection & Characterization
Based on NGS data (high copy number, strong enrichment, motif representation), 10-100 candidate sequences are chosen.
Synthesis & Initial Testing: Candidates are chemically synthesized and tested for binding affinity (e.g., via Surface Plasmon Resonance (SPR), Biolayer Interferometry (BLI), or ELISA-type assays) and specificity.
Lead Optimization: The top 1-5 aptamers may be truncated or mutated to find the minimal, optimal binding sequence.
5. Final Deliverables
Lead Aptamer Sequences: With binding affinity (Kd) and specificity data.
Comprehensive Report: Detailed methodology, NGS analysis, and characterization results.
Synthesized Aptamers: Vials of the lead aptamer(s) for your use.
| Advantage | Explanation |
|---|---|
| Speed | Reduces selection time from months to weeks (typically 6-10 weeks for the full service). |
| Higher Success Rate | NGS provides deep insights, preventing the loss of good binders that might be outcompeted early in traditional SELEX. |
| Data-Driven Decisions | You can see the entire enrichment landscape, not just the final pool. |
| Discovery of Rare Aptamers | Can identify high-affinity binders that are present at low frequencies in the early library. |
| Objective & Reproducible | Less subjective than cloning/Sanger sequencing of a few clones from the final pool. |
Target Compatibility: Discuss your target (size, purity, availability) upfront. Some providers specialize in small molecules, others in proteins or cells.
Modification Capabilities: For therapeutic/diagnostic applications, ask about modified nucleotide libraries (2′-F, 2′-O-methyl RNA, DNA-SOMAmer) to enhance nuclease resistance.
Bioinformatics Expertise: This is as crucial as the wet-lab work. Ask about their analysis pipeline and report depth.
Characterization Methods: What assays (SPR, BLI, etc.) do they use for Kd determination? Ensure they match your needs.
Project Cost & Timeline: Prices vary widely ($20,000 – $70,000+) depending on target complexity, number of rounds, and depth of characterization.
IP (Intellectual Property) Clarity: Understand who owns the resulting aptamer sequences. This is critical.
Timeline: 8-14 weeks from target receipt to characterized leads.
Output: Typically 3-5 lead aptamers with Kd values in the low nM to pM range, along with full data.
Aptamer Sciences Inc., Aptagen, LLC, NeoVentures Biotechnology, AptaDiscovery, Base Pair Biotechnologies are well-known commercial providers.
Many academic core facilities also offer HT-SELEX services.
HT-SELEX screening service is a turnkey solution for researchers who need high-affinity, specific aptamers but lack the specialized equipment and expertise. By leveraging NGS and bioinformatics, it provides a faster, more reliable, and insightful path to aptamer discovery than traditional methods, enabling applications in diagnostics, therapeutics, and research tools.
Before engaging, have a clear discussion with the provider about your target, application goals, and IP requirements to ensure a successful project.
Aptamer Screening Service-Multi-Round SELEX Screening
Aptamer Screening Service-NGS-SELEX
Aptamer Screening Service-Counter SELEX
Aptamer Screening Service-Subtractive SELEX
Aptamer Therapeutics
Aptamers as therapeutics
Aptamer Identification
Are there any FDA approved aptamer drugs?
What is the difference between an antibody and an aptamer?
What is aptamer used for?
APPLICATION OF APTAMERS IN TARGETED THERAPY OF LIVER CANCER
Aptamers for in vivo imaging of liver cancer
Toggle-SELEX Aptamer Screening Service
Negative Aptamer Selection- A Practical Guide to Improving Aptamer Specificity in SELEX
selexkmdbio-Cell Nucleic Acid Aptamer Screening Service
Aptamer Screening- Current Methods and Future Trend towards Non-SELEX Approach
Aptamer Screening Service-Subtractive SELEX
Aptamer Screening Service-Counter SELEX
Aptamer Screening Service-HT-SELEX
Aptamer Screening Service-NGS-SELEX
Aptamer Screening Service-Multi-Round SELEX Screening
Whole Cell-SELEX Aptamer Screening Service
Membrane Protein Aptamer Screening Service
Aptamer Screening Service for Drug Discovery
Aptamer Live Cell SELEX Service
Classical SELEX Service for Aptamer
Aptamer Selection and Identification
Aptamer Screening Process and Applications Overview